Fact-checked by Grok 2 weeks ago

Transurethral resection of the prostate

Transurethral resection of the prostate (TURP) is a minimally invasive that removes excess tissue obstructing urine flow, primarily to treat symptoms of in men. Performed endoscopically through the using a resectoscope equipped with a , camera, and wire loop, the trims away the inner tissue while preserving the prostate capsule, typically lasting 60 to 90 minutes under or spinal . Introduced in the , TURP remains the gold standard for managing moderate to severe BPH symptoms, such as urinary frequency, urgency, weak stream, and incomplete emptying, when medical therapies fail or complications like recurrent infections, stones, or acute arise. The procedure effectively improves urinary flow rates by an average of 10 mL/second and increases capacity, with approximately 90% of patients experiencing significant symptom relief that can last 10 to 15 years or more. Despite its efficacy, TURP carries potential risks, including in most cases, urinary tract infections, temporary incontinence, , and rare complications like TUR (hyponatremia from irrigation fluid absorption) or urethral strictures. Patients typically require a 1- to 3-day stay and use for 1 to 3 days postoperatively, with full recovery often achieved within weeks, though re-treatment may be needed in 10-15% of cases over time.

Background

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a nonmalignant condition characterized by the unregulated growth of prostate tissue, leading to enlargement of the gland without cancerous involvement. This histological diagnosis involves proliferation of , epithelial cells, and within the prostate. BPH becomes increasingly prevalent with age, affecting approximately 50% to 60% of men in their 60s and rising to 80% to 90% in those over 85 years, based on studies and clinical observations. The of BPH centers on hormonal influences and cellular imbalances that disrupt normal prostate homeostasis. Androgens, particularly (DHT) derived from testosterone via the enzyme 5-alpha-reductase, play a key role in promoting prostatic growth. This leads to an imbalance favoring cellular proliferation over , primarily in the transitional zone of the surrounding the . The resulting enlargement compresses the , contributing to obstructive effects, while associated and stromal remodeling further exacerbate the condition. BPH commonly manifests through (LUTS), which are categorized into storage and voiding subtypes. Storage symptoms include urinary frequency, (waking at night to urinate), and urgency, while voiding symptoms encompass a weak or intermittent stream, hesitancy, and straining. These symptoms arise from urethral obstruction and dysfunction. Complications such as acute urinary retention (AUR)—the sudden inability to pass urine—occur in about 1% to 2% of men with BPH annually, with cumulative risks reaching up to 10% over several years in older populations. Diagnosis of BPH typically begins with a digital rectal examination (DRE) to assess prostate size and consistency, often revealing an enlarged, smooth gland. Prostate-specific antigen (PSA) levels are measured to evaluate for potential malignancy, as elevated PSA can occur in BPH but helps differentiate it from prostate cancer. Uroflowmetry quantifies urine flow, with a peak flow rate below 15 mL/s suggesting obstruction in approximately 70% of cases, particularly when voided volume exceeds 150 mL. Post-void residual (PVR) urine measurement, ideally performed immediately after uroflowmetry, identifies incomplete emptying, with volumes over 100 mL indicating significant retention. For severe symptomatic BPH, procedures like transurethral resection of the prostate (TURP) may be considered as an intervention.

Overview of TURP

Transurethral resection of the prostate (TURP) is a minimally invasive endoscopic surgical procedure used to remove obstructing prostate tissue through the , without requiring external incisions. It addresses urinary symptoms caused by (BPH), the most common condition necessitating this intervention. The procedure employs a resectoscope to access and resect excess prostate tissue that compresses the , thereby alleviating bladder outlet obstruction. The primary goals of TURP are to relieve urethral obstruction and improve urinary function, typically resulting in a significant enhancement of peak urinary flow rates by an average of 10 mL/s and a reduction in (LUTS) by approximately 85%. This leads to better urine flow and decreased frequency of symptoms such as hesitancy and incomplete emptying. On average, the procedure involves resecting 20-40 grams of , with durations ranging from 30 to 90 minutes depending on prostate size and complexity. In TURP, an electrosurgical wire loop on the resectoscope cuts and coagulates under continuous to maintain visibility and flush debris. Non-conductive irrigants, such as 1.5% , are used in monopolar setups to prevent electrical conduction through the body. The resectoscope, often a continuous-flow model like the Iglesias type, facilitates precise removal while minimizing .

Indications and Patient Selection

Primary Indications

Transurethral resection of the prostate (TURP) is primarily indicated for men with (BPH) experiencing complications or persistent symptoms that impair . Absolute indications include conditions where conservative or medical management fails to prevent serious sequelae, such as refractory acute (AUR) secondary to BPH, where TURP relieves obstruction to restore voiding. Recurrent urinary tract infections (UTIs) attributable to BPH also warrant TURP, as unresolved obstruction promotes bacterial stasis and repeated episodes. Similarly, persistent gross due to BPH, recurrent bladder stones from incomplete emptying, and renal insufficiency (such as ) caused by bladder outlet obstruction are absolute triggers for intervention to avert further renal damage or hemorrhage. Relative indications encompass moderate-to-severe (LUTS) refractory to pharmacological therapy, typically defined by an International Prostate Symptom Score (IPSS) of 8 or greater, indicating significant bother from storage and voiding dysfunction. TURP is commonly pursued when multiple factors, including symptom severity and patient preference, converge after unsuccessful trials of alpha-blockers or 5-alpha reductase inhibitors. These scenarios often arise in the context of bothersome LUTS leading to clinical evaluation for BPH. TURP is most commonly performed in men aged 60 to 80 years with volumes of 30 to 80 grams, where the procedure effectively targets transitional zone causing obstruction. In selected patients meeting these criteria, TURP achieves success in improving in 80-90% of cases by alleviating symptoms and restoring normal voiding patterns.

Contraindications and Considerations

Transurethral resection of the prostate (TURP) has specific absolute contraindications that preclude its performance due to high risk of complications. These include an active, untreated (UTI), which must be resolved with antibiotics prior to surgery to prevent systemic spread or exacerbation during the procedure. Untreated represents another absolute contraindication, as it can lead to instrumentation failure or further trauma, necessitating prior management such as or urethrotomy. is generally contraindicated unless performed palliatively for severe (LUTS), as TURP is not curative and may complicate subsequent therapies like radiation or . Severe , such as an international normalized ratio (INR) greater than 1.5, is also absolute until corrected, given the procedure's reliance on normal to control bleeding. Relative contraindications require careful assessment and may favor alternative approaches like enucleation or open . A exceeding 80-100 grams is relative, as prolonged resection times increase risks of fluid absorption and complications, though skilled surgeons may extend to 150 grams with techniques. High post-void (>150 mL) or poor detrusor function (assessed via urodynamics) poses a relative due to potential incomplete emptying and higher incontinence rates post-procedure, warranting further . Neurological disorders affecting bladder control, such as , multiple sclerosis, or , are relative contraindications owing to elevated risks of and detrusor instability. Preoperative considerations emphasize thorough evaluation to mitigate risks and ensure suitability. Cardiac assessment is essential for tolerance in elderly patients, including electrocardiogram (ECG) and review of cardiovascular history to address fluid overload or risks. Preoperative use of alpha-blockers may be continued or initiated for symptom optimization in patients with moderate LUTS severity, aiding decompression without directly impacting , though 5-alpha reductase inhibitors like are preferred for vascular reduction if time allows. The American Urological Association (AUA) guidelines (2021, amended 2023 and finalized 2024) stress shared decision-making, incorporating patient preferences, size via transrectal , and post-void residual volume to weigh TURP against alternatives, particularly when bothersome moderate-to-severe LUTS (e.g., IPSS ≥8) guides initial assessment but barriers like comorbidities arise.

Surgical Procedure

Preoperative Preparation

Preoperative preparation for transurethral resection of the prostate (TURP) begins with a comprehensive diagnostic evaluation to confirm the appropriateness of the and assess characteristics. is routinely performed to visualize the , , and , allowing identification of any anatomical abnormalities or stones that could impact surgery. If a neurogenic is suspected, urodynamic studies are recommended to evaluate function, detrusor pressure, and voiding dynamics, helping to predict postoperative outcomes. Transrectal (TRUS) is often used to measure volume, guiding surgical planning as glands larger than 80 mL may require alternative approaches. Medication management is critical to minimize bleeding risks. Anticoagulants and antiplatelet agents, such as or clopidogrel, should be discontinued 5-7 days prior to , with bridging considered for patients at high thrombotic risk to maintain anticoagulation balance. For patients on 5-alpha-reductase inhibitors like , continuation for 2-6 weeks preoperatively can reduce vascularity and intraoperative blood loss by decreasing microvessel density, though longer-term use (up to 3 months) further shrinks size. Alpha-blockers may be continued or adjusted based on symptom control, while routine screening for urinary tract infections with culture and treatment if positive is essential. Additionally, prophylaxis is administered in accordance with current guidelines, typically as a single dose of an appropriate such as , to prevent postoperative infections. Anesthesia selection favors spinal over general in most cases due to lower cardiovascular and better hemodynamic stability during the . is obtained after discussing procedure benefits and risks, including a 70-90% incidence of as a common outcome from bladder disruption. Patients undergo standard preoperative fasting, remaining nil per os () for 6-8 hours to reduce risk under . A bowel may be administered if rectal emptying is needed to facilitate access, though it is not universally required.

Intraoperative Technique

The patient is positioned in the lithotomy stance with the buttocks placed at the edge of the cystoscopy table to facilitate straight-line access for the resectoscope, and the table is adjusted to an appropriate height for the surgeon's ergonomics. After initial cystoscopic examination to confirm urethral patency and identify key anatomical landmarks such as the verumontanum and ureteral orifices, the resectoscope sheath (typically 24-28 Fr) is lubricated and gently inserted through the urethra under direct vision using a visual obturator to avoid trauma. Continuous irrigation with an appropriate solution—nonconductive like glycine for monopolar TURP or isotonic saline for bipolar—is initiated, warmed to body temperature and maintained at a height of 60 cm above the table to provide an inflow of approximately 300 mL per minute for optimal visualization while minimizing intravesical pressure. The standard intraoperative technique follows the Nesbit method, originally described in 1943, which systematically resects prostatic tissue in defined stages to minimize bleeding and ensure complete adenoma removal while preserving continence. Resection begins with the intravesical stage, targeting the bladder neck and prostatic roof: starting at the 12-o'clock position, the cutting loop is withdrawn in long, smooth strokes to remove tissue in 1 cm chips clockwise around the bladder neck, creating a circumferential opening while avoiding the ureteral orifices. This is followed by the extravesical stage for the lateral lobes: the scope is repositioned just proximal to the verumontanum, and tissue is resected from the 5-7 o'clock (posterior) and 3-9 o'clock (lateral) positions, devascularizing and mobilizing the lobes toward the surgical capsule—a white, fibrous plane serving as the lateral —using curving strokes to drop the lobes posteriorly. The procedure concludes with the apical stage, approached with particular caution near the verumontanum to preserve the external urethral sphincter: a rectal finger may be used to elevate the apex for better exposure, and tissue is resected in small increments, stopping approximately 5 mm proximal to the verumontanum to avoid incontinence. Throughout, is achieved by coagulating visible vessels with the resectoscope loop in a blended cutting-coagulation mode, and resected chips are evacuated periodically using an Ellik evacuator to maintain clear visualization. The entire resection is typically completed in under 90 minutes to reduce fluid absorption risks, with complete removal of obstructing prioritized over exhaustive resection of non-obstructive tissue. Intraoperative monitoring focuses on , with input and output volumes tracked to ensure remains below 1 L—calculated as the difference between inflow and outflow—through frequent bladder checks and assessments. , including and mental status under , are observed continuously for early signs of TUR syndrome, such as or , prompting immediate if sodium falls below 125 mEq/L.

Variations of TURP

Monopolar TURP

Monopolar transurethral resection of the prostate (TURP) represents the traditional endoscopic approach to treating , building on the general TURP technique of resecting obstructing prostate tissue via a resectoscope inserted through the . In this method, electrical energy is delivered through a monopolar , where the active on the resectoscope loop vaporizes and coagulates tissue, while the return path completes via a grounding pad attached to the patient's skin. The electrical setup employs monopolar high-frequency current, typically set at 200-300 watts for cutting to enable precise tissue resection and 80-120 watts for to achieve . This configuration necessitates non-conductive irrigants, such as or solutions, to maintain visibility in the surgical field without short-circuiting the current; these fluids are hypotonic and non-electrolytic, allowing the monopolar energy to function effectively. Monopolar TURP offers established efficacy as the historical gold standard for managing bladder outlet obstruction due to benign prostatic hyperplasia, particularly for prostate volumes between 30 and 80 grams, where it provides reliable symptom relief and durable outcomes. However, its use of non-conductive irrigants carries a notable risk of electrolyte imbalance, including transurethral resection (TUR) syndrome from systemic absorption, which can lead to hyponatremia and associated complications. Additionally, the monopolar energy produces deeper tissue coagulation compared to alternatives, contributing to a higher incidence of urethral strictures, reported in 2-7% of cases. Since the introduction of bipolar TURP, monopolar TURP utilization has declined significantly, from nearly 100% of TURP procedures in the early 2000s to around 78% by 2013, reflecting a shift toward methods with potentially lower complication profiles.

Bipolar TURP

Bipolar transurethral resection of the prostate (TURP) represents a significant advancement in the surgical management of benign prostatic hyperplasia, utilizing bipolar radiofrequency energy to resect prostate tissue. In this technique, the electrical circuit is completed between the active resection loop electrode and the return electrode integrated into the resectoscope sheath, without requiring a separate grounding pad on the patient's skin. This configuration confines the current to the immediate vicinity of the resection site, enabling the use of isotonic saline (0.9% NaCl) as the irrigation medium, which is both conductive and physiologically compatible, thereby eliminating the risk of fluid absorption leading to transurethral resection (TUR) syndrome. The primary safety advantages of bipolar TURP stem from its irrigation compatibility and localized energy delivery. It virtually eliminates the incidence of dilutional , reporting 0% rates in multiple studies compared to 0.8-1.4% in monopolar TURP due to the avoidance of non-conductive, hypotonic irrigants like . Patients typically experience a shorter stay, averaging around 1-1.5 days, facilitating faster recovery and reduced healthcare resource utilization. Furthermore, the is particularly advantageous for patients with cardiac comorbidities, as the absence of a dispersive current path minimizes risks of arrhythmias or disturbances that could exacerbate underlying heart conditions. Despite these improvements, bipolar TURP is not without limitations. The more superficial coagulation effect may provide less deep hemostasis in highly vascular tissues, occasionally necessitating supplementary coagulation during surgery. The procedure also incurs higher costs attributable to specialized bipolar generators and resectoscopes. Long-term durability is comparable to other TURP variants, with reoperation rates of approximately 1-2% per year for recurrent symptoms or complications. Adoption of bipolar TURP has grown substantially since its introduction in the early 2000s, surpassing monopolar TURP in many institutions by the mid-2010s due to its superior safety profile, with guidelines from organizations like the American Urological Association endorsing its use alongside traditional methods.

Risks and Complications

Intraoperative Risks

During transurethral resection of the prostate (TURP), is a primary intraoperative concern, originating from capsular vessels and exacerbated in highly vascular prostates. Surgeons manage this by applying pressure to bleeding sites and using to achieve . The risk of significant hemorrhage necessitating is approximately 2-3% in standard cases, though rates can range from 0-9% and approach 5-10% in patients with larger or more vascular glands. TUR syndrome represents another critical intraoperative hazard, caused by systemic absorption of hypotonic irrigation fluid (typically solution) exceeding 1 L, resulting in dilutional and fluid overload. Early symptoms include , , visual disturbances, and , progressing to severe manifestations such as seizures or if untreated. The incidence is approximately 0.8-2% with monopolar TURP, significantly reduced by intraoperative monitoring of fluid and serum sodium levels, as well as limiting duration to under 90 minutes; bipolar TURP virtually eliminates this risk by using isotonic saline . Bladder or prostatic capsular perforation occurs rarely during TURP, with an incidence of less than 1%, typically resulting from excessive or blind resection in thin-walled areas such as the roof or capsule. This complication can lead to of irrigation fluid and sudden hemodynamic instability, managed by immediate cessation of resection, drainage via , and assessment for repair if needed. Anesthesia-related risks during TURP include , particularly under , which is a common complication due to sympathetic blockade; this is mitigated with vasopressor support and fluid management. Additionally, unrecognized capsular can open venous sinuses, causing acute and from rapid fluid absorption or vagal stimulation, emphasizing the need for vigilant monitoring of throughout the procedure.

Postoperative Complications

Postoperative complications following transurethral resection of the prostate (TURP) are categorized into early and late onset, with rates influenced by surgical technique, patient factors, and care. Early complications typically occur within the first few weeks and are often related to the immediate , while late complications may manifest months to years after due to remodeling or regrowth. Early postoperative complications include urinary tract infections (UTIs), which affect 2-10% of patients and are mitigated by routine prophylaxis to reduce and risk. Clot retention, occurring in approximately 2-5% of cases, often requires and can stem from intraoperative bleeding that leads to postoperative clot formation. , resulting from incision of the neck, is a common affecting 70-90% of patients and typically leads to dry , which is permanent in most cases. Late postoperative complications encompass , seen in 2-5% of patients due to from the resectoscope, and bladder neck contracture, occurring in 1-3% and more frequently with smaller prostates. , particularly if the is damaged, affects 1-2% of patients long-term, though transient incontinence is more common early on (up to 30-40%) and usually resolves. Sexual complications beyond are infrequent; is rare, with new-onset rates below 5% and erectile function preserved in over 90% of cases. Reoperation for prostatic regrowth is required in 1-2% of patients per year, accumulating to 10-15% at 10 years.

Recovery and Follow-up

Immediate Postoperative Care

Following transurethral resection of the prostate (TURP), patients are typically admitted to the hospital for 1 to 3 days to facilitate close monitoring and initial recovery. A three-way is inserted during and used for continuous (CBI) with normal saline to flush the and prevent blood clot formation, which could obstruct urine flow. The is maintained for 24 to postoperatively, with the flow rate adjusted to achieve light pink or "pink lemonade" colored effluent, and it is discontinued once the urine remains clear or only slightly pink for at least 24 hours. Prolonged CBI may be required if significant postoperative bleeding persists, extending the duration based on ongoing assessment. Key monitoring parameters in the immediate postoperative period include serial levels, serum electrolytes, and to detect complications such as hemorrhage or transurethral resection (TUR) syndrome. A drop of less than 2 g/dL is generally considered normal, reflecting typical blood loss of 200 to 400 mL during the , with levels checked within to confirm stability. Electrolytes, particularly sodium, are evaluated especially if the exceeded 60 minutes or involved excessive , to identify and resolve associated with TUR syndrome. are routinely assessed for signs of hemodynamic instability or , ensuring prompt if needed. Pain management focuses on alleviating and irritative symptoms common in the early recovery phase, with alpha-blockers such as tamsulosin (0.4 mg daily) recommended to relax the and neck, reducing discomfort without increasing risk. Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically avoided initially due to their potential to exacerbate postoperative . Mild analgesics may be used as needed for general discomfort. Discharge occurs once hematuria has cleared, CBI is discontinued, and urinary output exceeds fluid input by at least 1 L over 24 hours, confirming adequate voiding without retention. Patients receive education on catheter care if an indwelling is required beyond discharge, including signs of or obstruction to report, along with instructions for gradual resumption of activities.

Long-term Management

Following transurethral resection of the prostate (TURP), patients typically undergo follow-up clinic visits at 1 to 3 months postoperatively to assess symptom resolution and detect any early complications. These evaluations include administration of the International Prostate Symptom Score (IPSS) to quantify and uroflowmetry to measure peak urinary flow rate, with a target improvement to greater than 15 mL/s indicating successful outcomes. Subsequent visits may occur annually or as needed based on persistent symptoms or quality-of-life concerns. The durability of TURP is well-established, with 80-90% of patients experiencing sustained symptom relief at 5 years post-procedure, as measured by IPSS reductions and improved flow rates. Reoperation rates remain low in the long term, approximately 5% at 5 years and rising to about 15% at 10 years, often due to recurrent or stricture formation. Lifestyle modifications play a supportive role in long-term management, including exercises to potentially aid continence recovery, though evidence for their efficacy beyond the immediate postoperative period is limited. Patients are advised to avoid heavy lifting for 4-6 weeks to prevent strain on the surgical site, transitioning to general health practices thereafter. Ongoing (PSA) monitoring is recommended as part of routine , adjusted for the expected postoperative PSA decline. Quality-of-life improvements are a key benefit of TURP, particularly in reducing episodes by an average of 1 to 2 per night, though individual responses vary and some patients may experience persistent symptoms. Sexual function counseling is essential, as occurs in up to 70% of cases, though erectile function is generally preserved; patients should be informed of these changes to manage expectations and psychological impact.

Alternatives to TURP

Minimally Invasive Options

Minimally invasive options for (BPH) offer effective symptom relief with reduced recovery times and lower risks compared to more invasive procedures like TURP, particularly for patients seeking to preserve or those with comorbidities. These treatments target tissue reduction or retraction through endoscopic, thermal, embolic, or ablative methods, often performed outpatient under local or general . They are generally preferred for smaller prostates or high-surgical-risk individuals, providing durable improvements in (LUTS) while minimizing complications such as bleeding or . The UroLift system employs permanent nitinol implants to mechanically retract and compress lateral prostate lobes, widening the without , cutting, or removal. This approach is indicated for prostates measuring 20–100 cm³ (typically <80 cm³) and is performed as an outpatient procedure lasting 10–15 minutes. Clinical studies demonstrate significant LUTS relief, with 86% of patients achieving substantial symptom improvement within one month and sustained benefits up to five years, including reduced International Prostate Symptom Score (IPSS) and increased maximum urinary flow rate (Qmax). Ejaculatory function is preserved in nearly all cases, with no significant decline in antegrade ejaculation reported, making it suitable for sexually active patients prioritizing fertility or sexual satisfaction. Rezum therapy utilizes transurethral water vapor thermal ablation, delivering steam injections to denature prostate tissue via convective heat, leading to necrosis and volume reduction over weeks. Indicated for prostates measuring 30–80 cm³, it typically involves 4–10 injections per session in an outpatient setting, targeting central prostate zones while sparing the urethra and ejaculatory ducts. Five-year outcomes show durable symptom improvement, with mean IPSS reductions of about 50% (e.g., -10.3 points from baseline) and enhanced quality of life, alongside low retreatment rates. Sexual side effects are minimal, with no clinically meaningful impact on erectile function (International Index of Erectile Function change: -2.4 points) or ejaculatory preservation, positioning Rezum as a favorable option for patients with moderate BPH and concerns over sexual dysfunction. Prostatic artery embolization (PAE) reduces prostate blood supply by injecting embolic particles into feeding arteries, inducing ischemia, glandular atrophy, and smooth muscle relaxation to alleviate obstruction. This endovascular procedure, done under local anesthesia, is particularly suited for high-risk patients with comorbidities or anticoagulant use, as it avoids general anesthesia and surgical trauma. IPSS reductions of approximately 50-80% are reported, with some studies showing up to 81%, and 2024 systematic reviews confirming comparable efficacy to TURP at two years in symptom relief and quality of life, though with fewer complications (35.5% vs. 60.6%) and shorter hospital stays. PAE's non-invasive profile makes it ideal for frail individuals unfit for endoscopic surgery. Aquablation employs a robotically controlled, high-velocity waterjet guided by real-time ultrasound to precisely enucleate excess prostate tissue, sparing structures like the verumontanum to maintain ejaculatory pathways. Performed endoscopically in an operating room, it accommodates larger glands and ensures hemostasis via post-ablation cautery. The procedure preserves antegrade ejaculation in 90% of patients, markedly better than TURP's 64% rate, with similar LUTS improvements (e.g., IPSS reductions). Emerging 2025 data affirm its durability, with five-year follow-up showing sustained IPSS and Qmax gains without increased reintervention, highlighting its role for patients desiring long-term efficacy and sexual function preservation.

Open Surgical Alternatives

Open surgical alternatives to transurethral resection of the prostate (TURP) primarily involve procedures that directly excise the prostatic adenoma through an abdominal incision, reserved for cases where endoscopic approaches are less feasible. Simple open prostatectomy, the traditional method, employs either a suprapubic (transvesical) or retropubic (extravesical) approach to remove the hyperplastic tissue while preserving the prostate capsule and neurovascular structures. The suprapubic approach involves an incision into the bladder to access the adenoma from above, offering enhanced visualization of the bladder neck and adenoma base, whereas the retropubic approach accesses the prostate directly through the space anterior to the bladder, minimizing bladder manipulation but potentially complicating hemostasis. This procedure is indicated for prostates exceeding 80-100 grams, where TURP's operative time and irrigation fluid absorption risks become prohibitive for large volumes. Simple open prostatectomy achieves high success rates, with approximately 90% of patients experiencing sustained symptom relief and improved urinary flow rates at long-term follow-up, attributed to the complete removal of the adenoma. However, it carries a risk of urinary incontinence in 5-10% of cases, typically transient but occasionally requiring intervention, alongside other morbidities such as bleeding necessitating transfusion in 5-15% of patients. These outcomes reflect the procedure's durability for severe (BPH), though its invasiveness contributes to longer hospital stays and recovery periods compared to endoscopic options. Robotic-assisted simple prostatectomy represents a modern evolution, utilizing laparoscopic techniques with the da Vinci robotic system to perform adenoma enucleation through small ports, often via a transperitoneal retropubic or suprapubic route. This approach yields functional outcomes comparable to open surgery, including equivalent improvements in voiding symptoms and quality of life, but with reduced blood loss and shorter hospital stays. A 2023 meta-analysis confirmed similar efficacy to traditional open methods, highlighting robotic assistance's role in minimizing complications while accelerating recovery to 2-4 weeks versus 6 weeks for open procedures. Indications for open surgical alternatives over TURP include very large glands (>80-100 grams) and concomitant conditions such as stones or diverticula, where complete removal addresses multiple pathologies in a single operation. Despite these benefits, the procedures entail higher overall morbidity, including transfusion rates of 5-15%, due to the abdominal access and potential for significant hemorrhage. Historically, open constituted about 20% of BPH surgeries in the , serving as a mainstay before endoscopic advancements. By 2024, its utilization has declined to less than 5%, supplanted by less invasive techniques amid evolving guidelines favoring TURP and minimally invasive options for most patients.

History and Current Research

Historical Development

The development of transurethral resection of the prostate (TURP) built upon foundational advancements in endoscopic technology for treating (BPH), a condition causing urinary obstruction that has been recognized since ancient times. In 1877, Max Nitze invented the cystoscope, an illuminated endoscope that allowed visualization of the and , laying the groundwork for minimally invasive urological procedures. Early attempts at transurethral prostatectomy emerged in the 1920s, with urologist Hugh Hampton Young performing initial resections using a punch instrument equipped with an electric cautery blade to remove obstructing tissue. This approach was refined in 1926 when Maximilian Stern introduced the first resectoscope, a device incorporating a cystoscope with a cutting loop to resect prostatic tissue under direct vision, marking the birth of modern TURP. Further refinements in solidified TURP as a viable alternative to open surgery. Joseph F. McCarthy, collaborating with instrument maker Frederick Wappler, developed the Stern-McCarthy resectoscope in 1931, featuring improved visualization through a fore-oblique and enhanced electrical to control bleeding, which significantly reduced operative risks. By 1943, Reed M. Nesbit standardized the technique in his seminal textbook, describing a systematic method for complete resection that emphasized en bloc removal of chips and meticulous , promoting widespread adoption among urologists. Technological progress continued post-World War II, amid a temporary resurgence of open prostatectomy due to wartime shortages of electrical equipment and catheters. In 1945, Terence Millin introduced the retropubic open , but TURP regained prominence by the because of its lower morbidity, shorter stays, and reduced blood loss compared to open approaches. A major innovation came in 1975 with José M. Iglesias's resectoscope, which incorporated continuous irrigation and suction to maintain clear and low intravesical , minimizing complications like fluid absorption. TURP reached its zenith in the United States during the mid- to late , with approximately 350,000 procedures performed annually among beneficiaries by the 1980s, accounting for over 95% of BPH surgeries. However, the introduction of medical therapies in the 1990s, particularly alpha-blockers like and , offered non-surgical symptom relief and contributed to a sharp decline in TURP volume, with procedure rates dropping by about 40% by as pharmacological options became first-line treatments.

Ongoing Research and Advances

Recent studies have focused on techniques to preserve ejaculatory function during TURP, particularly ejaculation-preserving TURP (EP-TURP), which involves colliculus-preserving resection to minimize disruption to the ejaculatory ducts. A 2025 review highlights EP-TURP as a refinement of conventional TURP, achieving antegrade rates of 50-70% in selected patients, compared to approximately 10% with standard TURP. Another reported an 83% success rate for antegrade ejaculation using a similar sparing technique around the verumontanum and prostatic apex. Meta-analyses from 2024 and 2025 demonstrate that TURP provides comparable symptom relief to holmium laser enucleation of the prostate (HoLEP) and photoselective vaporization of the prostate (PVP), with International Prostate Symptom Score (IPSS) reductions of approximately 15 points across procedures for small-to-moderate prostate volumes. TURP is associated with comparable costs to HoLEP, averaging around $6,500 per procedure in analyses, with variations due to equipment and operative time expenses. For Aquablation, 2025 trials confirm equal durability to TURP at 5 years, with reoperation rates below 5% and sustained IPSS improvements in both large and small prostates. Advancements include enhancements in TURP for larger prostates (>80 mL), which reduce needs and transfusion risks compared to monopolar resection, enabling safer treatment of glands up to 100 g or more. Emerging applications, such as algorithms for predicting post-TURP urethral strictures, aid in resection planning and risk stratification to optimize outcomes. The 2024 AUA guideline (amended from 2023) and EAU guidelines endorse TURP as a first-line option for intermediate-risk (prostate volume 30-80 mL), emphasizing its efficacy and safety profile. Future directions emphasize transitioning TURP to outpatient settings, with 2023-2025 feasibility studies showing reduced hospital stays to under 24 hours without increased complications in low-risk patients. Adjunct therapies like preoperative aim to lower reoperation rates by minimizing bleeding and capsular perforation, potentially decreasing retreatment needs by 20-30% over 5 years.

References

  1. [1]
    Transurethral resection of the prostate (TURP) - Mayo Clinic
    Mar 21, 2024 · Transurethral resection of the prostate (TURP) is a common surgery that's used to treat urinary problems that are caused by an enlarged prostate.
  2. [2]
    Transurethral Resection of the Prostate - StatPearls - NCBI Bookshelf
    Sep 4, 2023 · TURP is a procedure where the prostate is resected from an endoscopic approach. It was the first major, minimally invasive surgery of the modern era.Continuing Education Activity · Indications · Preparation · Technique or Treatment
  3. [3]
    Transurethral resection of the prostate: MedlinePlus Medical Encyclopedia
    ### Summary of Transurethral Resection of the Prostate (TURP)
  4. [4]
    Benign Prostatic Hyperplasia - StatPearls - NCBI Bookshelf
    Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth or hyperplasia of prostate tissue and is a common cause of lower urinary tract symptoms ...Introduction · Epidemiology · Evaluation · Treatment / Management
  5. [5]
    Epidemiology and etiology of benign prostatic hyperplasia and ...
    Benign prostatic hyperplasia (BPH) is a histological diagnosis associated with unregulated proliferation of connective tissue, smooth muscle and glandular ...
  6. [6]
    The rising worldwide impact of benign prostatic hyperplasia - PMC
    The prevalence of histological BPH at autopsy increases substantially with age, reaching 90% in men aged 81–90 years [2].
  7. [7]
    Benign Prostatic Hyperplasia (BPH) - Medscape Reference
    Dec 24, 2024 · Prostatic enlargement depends on the potent androgen dihydrotestosterone (DHT). In the prostate gland, type II 5-alpha-reductase metabolizes ...
  8. [8]
    Review The role of the androgen receptor in prostate development ...
    Some of these symptoms of clinical BPH are the result of increased transition zone volume pushing on or occluding the urethra as well as extending the ...
  9. [9]
    Male Urinary Retention: Acute and Chronic - StatPearls - NCBI - NIH
    Over a 5-year time period, 10% of men older than 70 years and close to one-third in their 80s will develop acute urinary retention.[12][31] The primary male ...Etiology · Epidemiology · Evaluation · Treatment / Management
  10. [10]
    Acute Urinary Retention in Male Adults - DynaMed
    Apr 21, 2025 · Acute urinary retention is more common in male adults aged > 65 years or with benign prostatic hyperplasia (BPH). · 10% of male adults aged 70-79 ...
  11. [11]
    Benign prostatic hyperplasia (BPH) - Diagnosis and treatment
    Sep 24, 2024 · This exam is likely to include: Digital rectal exam. The provider inserts a finger into your rectum to check if your prostate is enlarged. Urine ...Missing: uroflowmetry peak
  12. [12]
    Importance of prostate volume and urinary flow rate in prediction of ...
    Approximately 70% of men with peak flow rate (Qmax) less than 15 ml/s are obstructed [10]. Value of other parameters of free flow is more controversial. Recent ...
  13. [13]
    The changing practice of transurethral resection of the prostate
    Transurethral resection of the prostate (TURP) is considered the gold standard surgical treatment for lower urinary tract symptoms (LUTS) secondary to benign ...
  14. [14]
    [PDF] Surgical Management of Lower Urinary Tract Symptoms Attributed to ...
    TURP remains the single best standard against which to measure the efficacy, effectiveness, and safety of other interventions for LUTS/BPH.
  15. [15]
    Benign Prostatic Hyperplasia: Rapid Evidence Review - AAFP
    Lower urinary tract symptoms from benign prostatic hyperplasia affect 25% of U.S. men, nearly one-half of whom have at least moderate symptoms.Missing: prevalence | Show results with:prevalence
  16. [16]
    EAU Guidelines on the Management of Non-neurogenic Male LUTS
    Bipolar- or M-TURP is the current standard surgical procedure for men with prostate sizes of 30-80 mL and bothersome moderate-to-severe LUTS secondary of BPO.
  17. [17]
    Transurethral Resection of the Prostate - Medscape Reference
    Dec 4, 2024 · Such indications include open surgical resection of a large bladder diverticulum or removal of a bladder stone that cannot be easily fragmented ...
  18. [18]
    How I treat anticoagulated patients undergoing an elective ...
    Before surgery, an INR of ≤ 1.5 is recommended.11,41 In many cases, the variability in decreasing INR over time warrants INR testing on the day before surgery.
  19. [19]
  20. [20]
    EAU Guidelines on the Management of Non-neurogenic Male LUTS
    These EAU Guidelines offer practical evidence-based guidance on the assessment and treatment of men aged 40 years or older with various non-neurogenic ...Disease Management · Diagnostic Evaluation · Methods · Follow Up
  21. [21]
    [PDF] EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL ...
    Recommendations for peri-operative management. Five days is an appropriate time to stop antiplatelet agents before surgery, while the optimal time to stop ...
  22. [22]
    Impact of preoperative 5α-reductase inhibitors on perioperative ...
    Jun 2, 2015 · Pretreatment with finasteride does seem to reduce perioperative blood loss related to TURP for BPH patients. This effect was probably due to ...Missing: blockers | Show results with:blockers<|control11|><|separator|>
  23. [23]
    EAU Guidelines on Urological Infections
    A urine culture must therefore be taken prior to such interventions and in case of ABU, pre-operative treatment is recommended. 3.3.5.6. Prior to orthopaedic ...
  24. [24]
    Anaesthesia for transurethral resection of the prostate | BJA Education
    May 4, 2009 · Spinal anaesthesia is regarded as the technique of choice for TURP, although there is little evidence to demonstrate significant difference in ...
  25. [25]
    Transurethral resection of the prostate with preservation of the ...
    The rate of retrograde ejaculation after TURP approximated 70–90% [18, 19]. ... Therefore, retrograde ejaculation was considered a physiological result of the ...
  26. [26]
    Transurethral Resection of Prostate | Journal of Endourology
    Sep 26, 2022 · The Nesbit procedure works around the lateral lobes along the capsule, dropping the lateral lobes one by one. The devascularized lateral lobes, ...
  27. [27]
    Analysis of Monopolar and Plasmakinetic Bipolar Cases - PMC - NIH
    Monopolar cautery, which requires external patient grounding and nonconductive irrigation solution (water, glycine, sorbitol, or mannitol), was the modality ...Missing: power conductive
  28. [28]
    A Prospective Randomized Comparative Study of Monopolar and ...
    Oct 1, 2013 · Power setting used was 160W for cutting and 80W for coagulation. The resection was carried down to the surgical capsule with the distal limit ...
  29. [29]
    A randomized comparison between three types of irrigating fluids ...
    May 28, 2010 · Glycine solution is the most commonly used irrigant in TURP ... electrical conducting properties prohibit its use with conventional monpolar TURP ...
  30. [30]
    Monopolar versus bipolar transurethral resection of prostate ... - NIH
    Monopolar transurethral resection of prostate (M-TURP) is considered the gold standard for the management of bladder outlet obstruction due to benign prostatic ...
  31. [31]
    Bipolar vs Monopolar Transurethral Resection of the Prostate in Iraqi ...
    The gold standard for treating symptomatic BPH associated with prostate volumes ranging between 30 and 80 cc is monopolar transurethral resection of the ...Missing: size | Show results with:size
  32. [32]
    Prostatic Artery Embolization for Benign Prostatic Hyperplasia
    In addition, monopolar TURP uses a non-conducting hypo-osmolar irrigation fluid (e.g., glycine) that can cause dilutional hyponatremia (low sodium ...
  33. [33]
    Complications of Transurethral Resection of the Prostate (TURP)
    The major late complications are urethral strictures (2.2–9.8%) and bladder neck contractures (0.3–9.2%). The retreatment rate range is 3–14.5% after five years ...Esut Special Paper · Abstract · Indications For TurpMissing: disadvantages | Show results with:disadvantages
  34. [34]
    Transurethral Resection of the Prostate with a Bipolar Tissue ... - NIH
    In conventional monopolar TURP, radiofrequency energy is directed into the tissue where electrical resistance creates temperatures as high as 400℃. In bipolar ...Missing: principles | Show results with:principles<|control11|><|separator|>
  35. [35]
    Study: Monopolar TURP utilization on the decline - Urology Times
    Feb 1, 2018 · He reported that the use of monopolar TURP has decreased significantly since the start of the study in 2003, but it's still the standard of care ...Missing: shift statistics<|control11|><|separator|>
  36. [36]
    Bipolar versus monopolar transurethral resection of the prostate for ...
    The bipolar circuit allows for use of a conductive and physiological irrigation medium, such as normal saline, and because less tissue resistance is encountered ...
  37. [37]
    Comparative Outcomes of Monopolar and Bipolar Transurethral ...
    Aug 27, 2024 · We used an energy current setting of 200 W for the cutting process and 120 W for coagulation. The bidirectional current flow enhances ...
  38. [38]
    [PDF] Transurethral Resection of the Prostate (TURP) Syndrome
    May 7, 2024 · ... However, it is used as an irrigation solution in bipolar TURP. The fluid absorbed from the prostatic venous channels is 20 ml/min.Missing: flow | Show results with:flow
  39. [39]
    Use of bipolar power source for transurethral resection of bladder ...
    In elderly patients and patients with cardiac or renal dysfunction the ability to resect without the fear of precipitating fluid and electrolyte imbalances ...
  40. [40]
    Reoperation after surgical treatment for benign prostatic hyperplasia
    Nov 9, 2023 · The reoperation rate of transurethral resection of the prostate (TURP) at 1, 2, 3, and 5 years was 4.0%, 5.0%, 6.0%, and 7.7%, respectively.Missing: per | Show results with:per
  41. [41]
    Management of Lower Urinary Tract Symptoms Attributed to Benign ...
    Jan 1, 2024 · This guideline seeks to improve clinicians' ability to evaluate and treat patients with BPH/LUTS based on currently available evidence.Missing: EAU | Show results with:EAU<|separator|>
  42. [42]
    TURP syndrome and severe hyponatremia under general anaesthesia
    Nov 19, 2012 · But, the symptoms of TURP syndrome and bladder perforation may be masked under sedation and general anaesthesia. Regional anaesthesia was ...
  43. [43]
    Fluid extravasation caused by bladder perforation during bipolar ...
    Perforation of the bladder during TURP has been reported many times, but its incidence was only 0.7% [2,3,8]. Patients with perforation usually complain of ...
  44. [44]
    Regional anesthesia in transurethral resection of prostate (TURP ...
    Spinal anesthesia is the technique of choice in transurethral resection of prostate (TURP). The major complication of spinal technique is risk of hypotension.Anaesthetic Procedure And... · Discussion · Table 5Missing: bleeding | Show results with:bleeding
  45. [45]
    Complications of transurethral resection of the prostate (TURP)
    The major late complications are urethral strictures (2.2-9.8%) and bladder neck contractures (0.3-9.2%). The retreatment rate range is 3-14.5% after five years ...
  46. [46]
    Risk Factors and Efficacy of Antibiotic Prophylaxis - PMC - NIH
    Sep 2, 2014 · Postoperative UTI and bacteremia are the principal complications after TURP; therefore, antibiotic prophylaxis is essential (17). However ...
  47. [47]
    Urinary incontinence following transurethral prostatectomy ... - NIH
    Jun 8, 2015 · After TURP, up to 30%–40% of patients may experience urinary incontinence in the early postoperative period; however, the incidence of late ...
  48. [48]
    Salvage Holmium laser enucleation of prostate to treat residual ...
    The calculated reoperation rate for TURP is 1.8% per year. Eight years after undergoing TURP, 12.0% to 15.5% of patients need re-intervention. Minimally ...
  49. [49]
    Transurethral resection of the prostate Information - Mount Sinai
    After the Procedure ... You will most often stay in the hospital for 1 to 3 days. In some cases, you may be allowed to go home the same day. After surgery, you ...
  50. [50]
    Transurethral Resection of the Prostate (TURP) - Cleveland Clinic
    TURP is surgery to remove part of your prostate. TURP can relieve symptoms of enlarged prostate, such as difficulty urinating and frequent urination.Missing: criteria output
  51. [51]
    Continuous Bladder Irrigation: Purpose & Procedure - Cleveland Clinic
    The healthcare provider will end continuous bladder irrigation once you have clear or only slightly pink urine for a day or two. The catheter is disconnected ...
  52. [52]
    [PDF] Correlation between post-operative electrolyte changes to ...
    Feb 1, 2023 · Post-operative change in laboratory parameters​​ The mean hemoglobin drop was 1.21 (±1.36) g/dl. The mean serum sodium drop was 1.55 (±3.01) mEq/ ...
  53. [53]
  54. [54]
    Management of prolonged post-operative pelvic pain after ... - NIH
    How do you treat patient with prolonged pelvic pain syndrome/prostatodynia after transurethral prostate surgery? (1) Alpha-blockers (e.g. tamsulosine). (2) 5- ...<|separator|>
  55. [55]
    Benign Prostatic Hyperplasia (BPH) Guideline
    Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic ...
  56. [56]
    5-year outcome of a prospective randomized trial to compare ...
    Conclusions: Our 5-year follow-up results confirm that TUVP is as effective as standard TURP in the treatment of moderate-size benign prostatic hyperplasia.
  57. [57]
    A Claims Based Assessment of Reoperation and Acute Urinary ...
    Feb 1, 2021 · At 7 years unadjusted cumulative failure rates were 15.3% for TURP, 13.9% for PVP, 6.7% for EEP and 17.8% for other procedures (p=0.04).
  58. [58]
    Impact of early pelvic floor rehabilitation after transurethral resection ...
    Our results show that pelvic floor muscle re-education produces a quicker improvement of urinary symptoms and of quality of life in patients after TURP.
  59. [59]
    Changes in Nocturia after Photoselective Vaporization of the ... - NIH
    The results of this study suggest that nocturia can improve significantly starting from the early postoperative period after PVP for symptomatic BPH.
  60. [60]
    Quality of Life and Sexual Function in Patients with Benign Prostatic ...
    As with TURP, 80%–90% of patients demonstrate improved symptoms. However, operating time is shorter, and less blood loss and fewer postoperative ...
  61. [61]
    Impact on Sexual Function of Endoscopic Enucleation vs ...
    There is a hypothesis that the postoperative improvement in LUTS will indirectly preserve sexual functions, especially EF, because the significant decreases in ...
  62. [62]
    Prostatic Urethral Lift - StatPearls - NCBI - NIH
    Aug 11, 2024 · The prostatic urethral lift (PUL) is a minimally invasive procedure to alleviate urinary symptoms in patients with benign prostatic hyperplasia.
  63. [63]
  64. [64]
    Preservation of Sexual Function 5 Years After Water Vapor Thermal ...
    Treatment for BPH with Rezum durably improved IPSS without clinically significant impact on sexual function. Patients with baseline ED/EjD may expect continued ...
  65. [65]
  66. [66]
    Prostate Artery Embolization as Minimally Invasive Treatment for ...
    Apr 25, 2024 · During a 12-month follow-up period, both PAE and TURP were comparable on the reduction in IPSS and QoL questionnaire, while TURP showed ...
  67. [67]
  68. [68]
    Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the ...
    Jun 9, 2025 · It is apparent there are significant sexual dysfunction side effects from 5 AR inhibitors, but the data do not suggest one 5 AR inhibitor ...
  69. [69]
  70. [70]
    Simple Prostatectomy: Overview, Preparation, Technique
    Dec 19, 2023 · The major advantage of the suprapubic approach over the retropubic approach is that it permits better visualization of the bladder neck and ...
  71. [71]
    Open suprapubic versus retropubic prostatectomy in the treatment of ...
    This study compared the suprapubic (SP) versus retropubic (RP) prostatectomy for the treatment of large prostates and evaluated perioperative surgical morbidity ...
  72. [72]
    Open simple prostatectomy and robotic ... - PubMed Central - NIH
    Jan 12, 2021 · Both OSP and RSP can produce excellent outcomes after surgery. However, complications of bleeding are significantly less prevalent in RSP.
  73. [73]
    Robotic-assisted simple prostatectomy: long-term, trifecta
    Jan 12, 2023 · Robotic-assisted simple prostatectomy (RASP) proved to be a sound and effective procedure for bladder outlet obstructive symptoms relief.
  74. [74]
    Recent advances in the surgical treatment of benign prostatic ...
    In 1999 TURP represented the 81% of surgical treatment for BPHversus 39% of 2005. Is this a marketing driven change or is there areal advantage in new ...
  75. [75]
    Benign Prostatic Hyperplasia Surgery: A Snapshot of Trends, Costs ...
    Apr 28, 2024 · Traditional surgery remained most performed for the entire period (87.8%), but a statistically significantly rising trend of NSTs was recorded.
  76. [76]
    Benign prostatic hyperplasia: A review of current trends in surgical ...
    Feb 26, 2021 · Transurethral resection of the prostate (TURP) developed following the invention of the cystoscope by Nitze in 1877, the first practical ...
  77. [77]
    TURP (Transurethral resection of the prostate)
    Hugh Hampton Young modified his urethroscope into a prostatic punch to cut tissue away from the bladder neck; he added an electric cautery blade in 1911. Both ...
  78. [78]
    The state of TURP through a historical lens - PubMed
    In 1926 Maximilian Stern introduced a new instrument to treat obstructions at the vesical orifice and baptized it resectoscope.
  79. [79]
    [PDF] History of the Transurethral Resection Syndrome
    Davis's improvement of the Stern resectoscope was the forerunner of the Stern- McCarthy instrument: (A) original Stern sheath with long beak and 5/8-inch ...
  80. [80]
    TURP | Urology News
    Mar 1, 2015 · The first resectoscope and hence the first TURP was introduced by Maximilian Stern (1843-1946) in 1926 in the USA (Figure 1). Figure 1 ...
  81. [81]
    New Iglesias resectoscope with continuous irrigation ... - PubMed
    The new Iglesias resectoscope that allows simultaneous suction, continuous irrigation and low intravesical pressure is described.
  82. [82]
    Transurethral Resection of the Prostate Versus Open Prostatectomy
    We found no supportive evidence that transurethral prostatectomy results in higher long-term mortality rates than does an open operation.Missing: shift | Show results with:shift
  83. [83]
    Current Medical Therapies for Men With Lower Urinary Tract ... - NIH
    The rapid decline of the use of TURP and other surgical procedures for BPH in the 1990s is due in part to the introduction of medical therapy; however, it ...
  84. [84]
    Research progress on ejaculatory function preservation in mi...
    Sep 30, 2025 · Ejaculation-preserving TURP (EP-TURP). EP-TURP is a technical refinement of conventional TURP, aiming to reduce the incidence of ...
  85. [85]
    Ejaculation-Preserving Transurethral Resection of the Prostate
    The ejaculation-sparing technique adopted in our study showed a promising result for preserving antegrade ejaculation following TURP with a success rate of 83%.Missing: EP- 2023-2025
  86. [86]
    GreenLight photoselective laser vaporisation versus transurethral ...
    May 30, 2025 · This meta-analysis suggests that PVP is non-inferior to TURP concerning IPSS, Qmáx, Vres, and complications, albeit with a longer operative time.<|separator|>
  87. [87]
    Evaluation of the Cost-Effectiveness of Surgical Treatment Options ...
    At 5 years, costs per patient for index patient 1 were $3292 (WVTT), $6532 (HoLEP), $6670 (B-TURP), and $10,257 (PUL). HoLEP resulted in the highest QALYs (4.66) ...
  88. [88]
    WATER versus WATER II 5‐year update: Comparing Aquablation ...
    Sep 9, 2024 · This study aims to compare the long-term outcomes of Aquablation for small-to-moderate (30–80 cm 3 ) prostates with the outcomes for large (80–150 cm 3 ) ...2 Patients And Methods · 3 Results · 4 Discussion
  89. [89]
    National Trends in Surgical Management for Benign Prostatic ...
    Mar 1, 2024 · Recent advancements in bipolar TURP technologies aim to reduce side effects compared to traditional monopolar resection methods. Bipolar ...
  90. [90]
    Machine learning algorithm predicts urethral stricture following ...
    May 15, 2024 · To predict the post transurethral prostate resection(TURP) urethral stricture probability by applying different machine learning algorithms.
  91. [91]
    Does dutasteride reduce the bleeding in transurethral resection of ...
    A 4-week treatment with dutasteride does not significantly reduce TURP-associated bleeding but could reduce the duration and amount of postoperative bladder ...Missing: adjunct 2023-2025